ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 029,85
0,46%
Dow Jones
38 646,08
-0,10%
DAX
18 678,81
1,06%
Brent Oil
80,095
-0,88%
Bitcoin
69 876,74
3,14%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ATAI Life Sciences NV (ATAI)

  7. ATAI Life Sciences NV (ATAI) Actualités

ATAI

ATAI Life Sciences NV (ATAI)

ATAI Life Sciences NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATAI
DateHeureSourceTitreSymboleSociété
31/05/202413h00GlobeNewswire Inc.atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare ConferenceNASDAQ:ATAIATAI Life Sciences NV
23/05/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
23/05/202413h00GlobeNewswire Inc.atai Life Sciences Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:ATAIATAI Life Sciences NV
20/05/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
15/05/202413h53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATAIATAI Life Sciences NV
15/05/202412h59GlobeNewswire Inc.atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
24/04/202413h00GlobeNewswire Inc.atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
17/04/202413h00GlobeNewswire Inc.atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyNASDAQ:ATAIATAI Life Sciences NV
28/03/202412h00GlobeNewswire Inc.atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsNASDAQ:ATAIATAI Life Sciences NV
27/03/202412h00GlobeNewswire Inc.atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
04/03/202414h00GlobeNewswire Inc.atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01NASDAQ:ATAIATAI Life Sciences NV
28/02/202423h00GlobeNewswire Inc.atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceNASDAQ:ATAIATAI Life Sciences NV
13/02/202422h29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATAIATAI Life Sciences NV
06/02/202423h00GlobeNewswire Inc.atai Life Sciences Appoints Anne Johnson as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
04/01/202413h00GlobeNewswire Inc.atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsNASDAQ:ATAIATAI Life Sciences NV
02/01/202414h00GlobeNewswire Inc.atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)NASDAQ:ATAIATAI Life Sciences NV
14/11/202313h03GlobeNewswire Inc.atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ATAIATAI Life Sciences NV
10/10/202314h00PR Newswire (Canada)ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORTNASDAQ:ATAIATAI Life Sciences NV
06/10/202322h05GlobeNewswire Inc.atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:ATAIATAI Life Sciences NV
02/10/202322h13GlobeNewswire Inc.atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsNASDAQ:ATAIATAI Life Sciences NV
14/09/202314h02GlobeNewswire Inc.atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ATAIATAI Life Sciences NV
06/09/202322h01GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming September Investor ConferencesNASDAQ:ATAIATAI Life Sciences NV
10/08/202312h59GlobeNewswire Inc.atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)NASDAQ:ATAIATAI Life Sciences NV
08/08/202322h02GlobeNewswire Inc.atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)NASDAQ:ATAIATAI Life Sciences NV
01/06/202315h10GlobeNewswire Inc.Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
01/06/202312h59GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming June Investor ConferencesNASDAQ:ATAIATAI Life Sciences NV
31/05/202313h56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATAIATAI Life Sciences NV
25/05/202322h29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATAIATAI Life Sciences NV
19/05/202323h37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ATAIATAI Life Sciences NV
11/05/202322h19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATAIATAI Life Sciences NV
 Showing the most relevant articles for your search:NASDAQ:ATAI

Dernières Valeurs Consultées

NYSE
SPIR
Spire Global
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés